286 filings
Page 4 of 15
8-K
ujm3 hk1r2fuk7
5 Feb 21
Other Events
12:00pm
8-K
mvaeq6pn2k0ne
29 Jan 21
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
6:55am
8-K
m66ansee24sz6 msv
22 Jan 21
Changes in Registrant's Certifying Accountant
7:30am
8-K
5hvn4m26gl6h42d05
23 Dec 20
Entry into a Material Definitive Agreement
5:20pm
8-K
k7qixk53cw3 uewg
11 Dec 20
Departure of Directors or Certain Officers
8:00am
8-K
fwk7ccm7l9xdlygupk
23 Nov 20
Regulation FD Disclosure
9:05am
8-K
z8tsns jn
20 Nov 20
Other Events
5:25pm
8-K
sl6bsi
7 Oct 20
Submission of Matters to a Vote of Security Holders
4:52pm
8-K
oxs3wblylbsav
6 Oct 20
AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen
9:10am
8-K
cye0c q8wequk
5 Oct 20
Regulation FD Disclosure
4:05pm
8-K/A
kdn0sk
31 Aug 20
Regulation FD Disclosure
1:09pm
8-K
c9fr82 c1sf
31 Aug 20
Regulation FD Disclosure
7:30am
8-K
4uo 8077d
3 Aug 20
Regulation FD Disclosure
6:30am
8-K
xf17 93adp
9 Jul 20
Agreement Important Precursor to Next Step, Enrollment
7:00am
8-K
0jpb0p xco2
6 Jul 20
AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan’s National
9:00am
8-K
vtn427 0zaghw0iuue
24 Jun 20
Entry into a Material Definitive Agreement
9:00am
8-K
iuwhpo1ob7q4 ihq
15 Jun 20
AIM ImmunoTech Provides Update on Commercial Launch of Ampligen® in Argentina for the Treatment of Chronic Fatigue Syndrome
1:56pm
8-K
kqmevh5q7226e
5 Jun 20
Entry into a Material Definitive Agreement
5:00pm
8-K
8d6zcv9wzjv11u hrawq
27 Apr 20
Entry into a Material Definitive Agreement
5:13pm
8-K
pud86 d4qfd9wxh9
16 Apr 20
Results of Operations and Financial Condition
5:00pm